丹红通经方联合常规西药治疗急性脑梗死临床疗效及对血清C反应蛋白与神经功能缺损的影响

摘要

目的 分析在常规西药基础上加用丹红通经方治疗急性脑梗死的临床疗效及对血清C反应蛋白(CRP)与神经功能缺损的影响.方法 抽取2015年2月-2016年1月我院78例急性脑梗死病人,根据不同治疗方案分组,各39例.对照组采用依达拉奉治疗,研究组联合采用依达拉奉+丹红通经方治疗,两组均持续治疗14 d.对比治疗前后两组神经功能缺损评分(NIHSS)、血清C反应蛋白水平变化情况,并统计两组临床疗效及不良反应发生率.结果 治疗前两组NIHSS评分、CRP水平对比差异无统计学意义(P>0.05),经治疗,两组均较治疗前改善,且研究组NIHSS(7.51±2.65)分、CRP(7.01±2.32)mg/L,均优于对照组[(11.73±7.22)分、(14.03±5.01)mg/L],差异有统计学意义(P<0.05);两组治疗总有效率对比,研究组(92.31%)高于对照组(74.36%),差异有统计学意义(P<0.05);研究组不良反应发生率(10.25%)与对照组(12.81%)相比差异无统计学意义(P>0.05).结论 急性脑梗死在常规西药治疗基础上加用丹红通经方效果显著,可有效降低血清CRP水平,改善病人神经功能,提高治疗效果,且不会增加不良反应发生率,安全性较高.%Objective To analyze the clinical curative effect of Danhong Tongjing formula (DTF) and conventional western medicine in the treatment of acute cerebral infarction (ACI) and its influence on serum C-reactive protein (CRP) and nerve function defect.Methods Seventy-eight patients with ACI were selected from February 2015 to January 2016 and divided into two groups:control group (n=39) treated with edaravone,and treatment group(n=39) treated with edaravone and DTF for 14 days.The National Institutes of Health Stroke Scale (NIHSS), serum C reactive protein (CRP) levels were observed before and after treatment.The clinical efficacy and adverse reaction were observed.Results After treatment, NIHSS scores and CRP levels in treatment group were lower than that in control group [(7.51 ± 2.65) vs (11.73 ±7.22) , P<0.05;(7.01± 2.32) mg/L vs (14.03± 5.01) mg/L, P<0.05].The total efficiency in treatment group was higher than that in control group (92.31% vs 74.36%, P<0.05).The incidence of adverse reaction was 10.25% in treatment group and 12.81% in control group (P>0.05).Conclusion DTF and conventional western medicine can effectively reduce the level of serum CRP, improve neurological function, improve the therapeutic effect, and does not increase the incidence of adverse reaction.